Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $497 | In Stock | |
5 mg | $1,230 | In Stock | |
10 mg | $1,990 | In Stock | |
25 mg | $2,960 | In Stock | |
50 mg | $3,920 | In Stock | |
100 mg | $5,380 | In Stock |
Description | Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody against phosphatidylserine (PS) with vascular targeting and immunomodulatory properties. It can reactivate anti-tumor immunity to inhibit tumor growth. Bavituximab has anti-cancer activity and is often used in combination with Paclitaxel and Carboplatin to study non-small cell lung cancer. |
In vitro | Bavituximab binds to exposed phosphatidylserine (PS) molecules through the serum protein β2-glycoprotein 1 (β2GP1)[1]. Bavituximab induces antibody-dependent cellular cytotoxicity by binding to PS, leading to the destruction of tumor vessels[1]. Bavituximab (10 μg/mL; 48 h) binds to exposed phosphatidylserine (PS) induced by 10 μM Sorafenib in HUVEC and bEnd.3 cells[2]. |
In vivo | Sorafenib induces exposure of anionic phospholipids in a mouse tumor model. Bavituximab (100 μg/mouse; i.v.; single dose; administered 48 h after Sorafenib treatment) detects phosphatidylserine exposure in vivo[2]. |
Alias | Anti-PS MAb 3G4 |
Cas No. | 648904-28-3 |
Storage | store at low temperature store at -80°C |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.